| Autor: |
Abouali H; Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada., Hosseini SA; Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada., Purcell E; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109-2800, USA., Nagrath S; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109-2800, USA., Poudineh M; Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada. |
| Jazyk: |
angličtina |
| Zdroj: |
Cancers [Cancers (Basel)] 2022 Jan 07; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 07. |
| DOI: |
10.3390/cancers14020288 |
| Abstrakt: |
During cancer progression, tumors shed different biomarkers into the bloodstream, including circulating tumor cells (CTCs), extracellular vesicles (EVs), circulating cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA). The analysis of these biomarkers in the blood, known as 'liquid biopsy' (LB), is a promising approach for early cancer detection and treatment monitoring, and more recently, as a means for cancer therapy. Previous reviews have discussed the role of CTCs and ctDNA in cancer progression; however, ctDNA and EVs are rapidly evolving with technological advancements and computational analysis and are the subject of enormous recent studies in cancer biomarkers. In this review, first, we introduce these cell-released cancer biomarkers and briefly discuss their clinical significance in cancer diagnosis and treatment monitoring. Second, we present conventional and novel approaches for the isolation, profiling, and characterization of these markers. We then investigate the mathematical and in silico models that are developed to investigate the function of ctDNA and EVs in cancer progression. We convey our views on what is needed to pave the way to translate the emerging technologies and models into the clinic and make the case that optimized next-generation techniques and models are needed to precisely evaluate the clinical relevance of these LB markers. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
